Franco Rutili

Renovacor is a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and related diseases. The company’s lead program in BAG3-associated dilated cardiomyopathy (DCM) uses gene transfer technology to address the monogenic cause of this severe form of heart failure. Renovacor’s vision is to bring life-changing therapies to patients living with serious genetic cardiovascular and related diseases, by developing medicines that target the underlying cause of disease and provide a transformative benefit and significant improvement to quality of life.

Menarini Silicon Biosystems offers unique rare cell technologies and solutions that provide clinical researchers with access to unparalleled resolution in the study of cells and their molecular characterization. The company’s CELLSEARCH® and DEPArray™ technologies together provide an end-to-end solution for enumeration and sorting of rare cells with single-cell precision. Menarini Silicon Biosystems, based in Bologna, Italy, and Huntingdon Valley, PA, US, is a wholly-owned subsidiary of the Menarini Group, a multinational pharmaceutical, biotechnology, and diagnostics company headquartered in Florence, Italy, with 17,640 employees in 136 countries. Read our Netiquette here: www.siliconbiosystems.com/netiquette

Renovacor is a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and related diseases. The company’s lead program in BAG3-associated dilated cardiomyopathy (DCM) uses gene transfer technology to address the monogenic cause of this severe form of heart failure. Renovacor’s vision is to bring life-changing therapies to patients living with serious genetic cardiovascular and related diseases, by developing medicines that target the underlying cause of disease and provide a transformative benefit and significant improvement to quality of life.

Menarini Silicon Biosystems offers unique rare cell technologies and solutions that provide clinical researchers with access to unparalleled resolution in the study of cells and their molecular characterization. The company’s CELLSEARCH® and DEPArray™ technologies together provide an end-to-end solution for enumeration and sorting of rare cells with single-cell precision. Menarini Silicon Biosystems, based in Bologna, Italy, and Huntingdon Valley, PA, US, is a wholly-owned subsidiary of the Menarini Group, a multinational pharmaceutical, biotechnology, and diagnostics company headquartered in Florence, Italy, with 17,640 employees in 136 countries. Read our Netiquette here: www.siliconbiosystems.com/netiquette